At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 2, 2026 at 08:00 ET
UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the commercial launch of ZUSDURI ($15.8M in sales) and 7% underlying growth in JELMYTO sales ($94M). The company refinanced its debt with Pharmakon Advisors for $200M in non-dilutive capital, strengthening its balance sheet. Despite higher R&D and SG&A expenses, management expressed confidence in ZUSDURI's launch trajectory following the January 2026 effective J Code, and provided 2026 JELMYTO sales guidance of $97M–$101M.
- ZUSDURI achieved $15.8 million in net sales in 2025, its first full year post-FDA approval (June 2025).
- JELMYTO generated $94.0 million in 2025, reflecting 7% year-over-year underlying demand growth.
- Total revenue increased 21% YoY to $109.8 million in 2025.
- Net loss widened to $153.5 million ($3.19/share) in 2025 from $126.9 million ($2.96/share) in 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access